Affiliation:
1. University Hospitals of Morecambe Bay NHS Foundation Trust
2. University of Birmingham
3. University of Western Australia
4. Medicines and Healthcare Products Regulatory Agency
5. Long Covid SOS, Charity registered in England & Wales
Abstract
Abstract
Background
The economic impact of managing long COVID in primary care is unknown. We estimated the costs of primary care consultations associated with long COVID and explored the relationship between risk factors and costs.
Methods
Data were obtained on non-hospitalised adults from the Clinical Practice Research Datalink Aurum primary care database. We used propensity score matching with an incremental cost method to estimate additional primary care consultation costs associated with long COVID (12 weeks after COVID-19) at an individual and UK national level. We applied multivariable regression models to estimate the association between risk factors and consultations costs beyond 12 weeks from acute COVID-19.
Results
Based on an analysis of 472,173 patients with Covid-19 and 472,173 unexposed individuals, the annual incremental cost of primary care consultations associated with long COVID was £2.44 per patient and £23,382,452 at the national level. Among patients with COVID-19, a long COVID diagnosis and longer-term reporting of symptoms were associated with a 43% and 44% increase in primary care consultation costs respectively, compared to patients without long COVID symptoms. Older age, female sex, obesity, being from a white ethnic group, comorbidities and prior consultation frequency were all associated with increased primary care consultation costs.
Conclusions
The costs of primary care consultations associated with long COVID in non-hospitalised adults are substantial. Costs are significantly higher among those diagnosed with long COVID, those with long COVID symptoms, older adults, females, and those with obesity and comorbidities.
Publisher
Research Square Platform LLC
Reference30 articles.
1. World Health Organisation (WHO). A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021 [Internet]. 2021 Oct 06. [Cited 22/04/2022]. Available at: https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1.
2. 2022 Mar 01. [Cited 12/04/2022]. Available at: https://www.nice.org.uk/guidance/ng188/resources/covid19-rapid-guideline-managing-the-longterm-effects-of-covid19-pdf-51035515742#:~:text=In%20addition%20to%20the%20clinical,(12%20weeks%20or%20more). National Institute for Health and Care Excellence (NICE). COVID-19 rapid guideline: managing the long-term effects of COVID-19 [Internet]. NICE, Chen C, Haupert SR, Zimmermann L, Shi X, Fritsche LG, Mukherjee B. Global prevalence of post-Coronavirus disease 2019 (COVID-19) condition or long COVID: A meta-analysis and systematic review. J Infect Dis [Internet]. 2022;226(9):1593–607. Available from: http://dx.doi.org/10.1093/infdis/jiac136.
3. COVID-19 map. Johns Hopkins Coronavirus Resource Centre. [cited 2022 Nov 20]. Available from: https://coronavirus.jhu.edu/map.html.
4. Global Burden of Disease Long, Collaborators COVID, Wulf Hanson S, Abbafati C, Aerts JG, Al-Aly Z, Ashbaugh C et al. Estimated global proportions of individuals with persistent fatigue, cognitive, and respiratory symptom clusters following symptomatic COVID-19 in 2020 and 2021. JAMA. 2022;328(16):1604–15. Available from: http://dx.doi.org/10.1001/jama.2022.18931.
5. Office for National Statistics. Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK: 7 July 2022 [Internet]. 7 Jul 2022 [cited 13/07/2022]. Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/7july2022.